Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
CSE: AIML
OTCQB: AIMLF
FWB: 42FB
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
Read more in Archive
January 28, 2026
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
Read More
January 20, 2026
AIML subsidiary NeuralCloud Collaborates with Movesense to Expand Bundled ECG Solutions for Clinical and Wellness Markets
Read More
January 8, 2026
AIML subsidiary NeuralCloud Solutions Inc., Signs Non-Binding Commercial Term Sheet with Lakeshore Cardiology to Deploy CardioYield™ for AI-Powered Holter Analysis
Read More
January 7, 2026
AIML Appoints Erik Suokas as Chief Operating Officer to Accelerate Commercial Execution and Operational Scale
Read More
December 30, 2025
AIML Announces the Conclusion of Consulting Agreement and Leadership Transition for President & Chief Commercial Officer
Read More
December 16, 2025
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
Read More
Full Recording of 2025 Shareholder Update
AIML’s 2025 Shareholder Update from CEO & Executive Chairman, Paul Duffy, outlining key milestones from 2025 - including Product Development, Commercial Traction, and Regulatory Progress - along with the roadmap for 2026. The livestream concludes with a Q&A with the live audience.
Visit pageCorporate Governance
Board of Directors
Financials
Read more on CSE
Read more
Charters & Policies
Company Structure
253.9
Million
Shares Outstanding
16
Million
Options
190.7
Million
Warrants Outstanding
460.6
Million
Fully Diluted